Clinical trials: B Cell
Burkitt's Lymphoma, Burkitt'S-like Lymphoma
Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma
The goal of this clinical research study is to learn if intensive chemotherapy given over 6 months can help to control or cure Burkitt's leukemia, Burkitt's lymphoma, or small non-cleaved cell B-cell leukemia or lymphoma.
- Trial name
- NCT00669877
- Testing
- Rituximab, Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- M.D. Anderson Cancer Center
B-Cell Non-Hodgkin Lymphoma (NHL)
Non-Interventional Study of Ranicabtagene Autoleucel Injection for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Establishing real-world data of patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) treated with Ranicabtagene Autoleucel Injection to evaluate its efficacy and safety.
- Trial name
- NCT07888530
- Testing
- Ranicabtagene Autoleucel Injection
- Volunteers
- 200 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Ublituximab + Ibrutinib in Select B-cell Malignancies
The purpose of this study is to evaluate the safety and effectiveness of Ublituximab in combination with Ibrutinib in patients with advanced hematologic malignancies.
- Trial name
- NCT02013128
- Testing
- Ublituximab, Ibrutinib
- Where
- 18 sites in United States
- Volunteers
- 66 people
- Sponsor
- TG Therapeutics, Inc.
Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
This is an open-label, multicenter, phase 2 clinical trial to evaluate the efficacy and safety of brentuximab vedotin as a single agent in patients with CD30-positive non-Hodgkin lymphoma (NHL) (Part A).
- Conditions
- Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell
- Trial name
- NCT01421667
- Testing
- brentuximab vedotin, rituximab
- Where
- 34 sites in United States, Canada
- Volunteers
- 176 people
- Sponsor
- Seagen Inc.
MYC Positive, Recurrent B-Cell Non-Hodgkin Lymphoma
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas
This phase I trial studies the side effects and best dose of alisertib and romidepsin in treating patients with B-cell or T-cell lymphomas that have returned after a period of improvement (relapsed) or have not responded to…
- Conditions
- MYC Positive, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
- Trial name
- NCT01897012
- Testing
- Alisertib, Laboratory Biomarker Analysis, Romidepsin
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Sclerosis, Neuromyelitis Optica
Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B
First in human study to assess the tolerability and safety profile of treatment with dendritic cell in patients with multiple sclerosis or neuromyelitis optica.
- Trial name
- NCT02283671
- Testing
- Tolerogenic Dendritic cells loaded with myelin peptides
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Sara Varea
Leukemia
Biomarkers in Samples From Patients With B-Cell Acute Lymphoblastic Leukemia
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT01505699
- Testing
- RNA analysis, cytogenetic analysis, microarray analysis
- Volunteers
- 186 people
- Sponsor
- Eastern Cooperative Oncology Group
Lymphoma, Follicular, Lymphoma, Mantle-Cell
A Phase 1 Study of ADI-001 in B Cell Malignancies
This is a Phase 1 dose escalation study following a 3+3 study design. The purpose of this study is to evaluate the safety and efficacy of ADI-001 in patients with B cell malignancies.
- Conditions
- Lymphoma, Follicular, Lymphoma, Mantle-Cell, Marginal Zone Lymphoma, Primary Mediastinal B-cell Lymphoma
- Trial name
- GLEAN-1 (NCT04735471)
- Testing
- ADI-001, Fludarabine, Cyclophosphamide
- Where
- 10 sites in United States
- Volunteers
- 34 people
- Sponsor
- Adicet Therapeutics
Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma
Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma
This phase II trial studies how well bortezomib and vorinostat work in treating patients with recurrent mantle cell lymphoma or recurrent and/or refractory diffuse large B-cell lymphoma.
- Trial name
- NCT00703664
- Testing
- Bortezomib, Laboratory Biomarker Analysis, Vorinostat
- Where
- 12 sites in United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Haemophilus Influenzae Type b, Diphtheria
Immuno & Safety Study With 2 Formulations of DTPw-HBV/HIB When Given at Birth With Hepatitis B at 2, 4 and 6 Mths.Age.
A trial to characterize the immunogenicity of 2 different formulations of a vaccine from GSK Biologicals, including the following five antigens: diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b.
- Conditions
- Haemophilus Influenzae Type b, Diphtheria, Tetanus, Hepatitis B
- Trial name
- NCT00316680
- Testing
- Diphtheria, tetanus, pertussis, hepatitis B, Hib vaccine
- Where
- Dominican Republic
- Volunteers
- 288 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Lymphoma, Non Hodgkin
MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma
This open-label, single-arm, phase IIIb study will evaluate the safety of switching from intravenous (IV) to subcutaneous (SC) administration of rituximab during first-line treatment for participants with CD20+ non-Hodgkin's…
- Trial name
- NCT01987505
- Testing
- Rituximab
- Where
- 39 sites in Spain
- Volunteers
- 140 people
- Sponsor
- Hoffmann-La Roche
Diffuse Large B Cell Lymphoma, Mediastinal Large B-cell Lymphoma
Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
This phase II trial studies how well brentuximab vedotin, bendamustine, and rituximab work in treating patients with B-cell non-Hodgkin lymphoma that has returned after a period of improvement or has not responded to previous…
- Conditions
- Diffuse Large B Cell Lymphoma, Mediastinal Large B-cell Lymphoma, Grey Zone Lymphoma, High Grade B Cell Lymphoma
- Trial name
- S-BR (NCT02623920)
- Testing
- Brentuximab, Bendamustine, Rituximab
- Where
- United States
- Sponsor
- University of Arizona
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia
Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia
This phase II trial studies the side effects and how well combination chemotherapy and ponatinib hydrochloride work in treating patients with acute lymphoblastic leukemia.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Trial name
- NCT01424982
- Testing
- Cyclophosphamide, Cytarabine, Dexamethasone
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- M.D. Anderson Cancer Center
Bladder Cancer, Breast Cancer
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
RATIONALE: Physician-initiated smoking cessation strategies may be effective in getting early-stage cancer patients to quit smoking.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT00002520
- Testing
- nicotine, Usual Care
- Where
- United States
- Volunteers
- 434 people
- Sponsor
- Eastern Cooperative Oncology Group
Advanced Solid Tumor, B Cell Lymphoma
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1
This study is the first-in-human clinical trial of CN1 to evaluate the safety, tolerability, pharmacokinetic (PK) profile and preliminary efficacy of CN1 in patients with advanced solid tumors or B-cell lymphoma.
- Trial name
- NCT04418141
- Testing
- CN1
- Where
- Austria
- Volunteers
- 13 people
- Sponsor
- Curon Biopharmaceutical (Australia) Co Pty Ltd
Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue
This is an open label, phase II study to evaluate the capacity of Rituximab (Mabthera®) plus Lenalidomide (Revlimid®) to induce objective responses in patients with Mucosa Associated Lymphoid Tissue (MALT) lymphoma presenting…
- Trial name
- NCT01611259
- Testing
- Rituximab and Lenalidomide
- Where
- 5 sites in Austria
- Volunteers
- 50 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Large B-Cell Lymphoma
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
The purpose of this study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs Pola-R-CHP in participants with…
- Trial name
- NCT06047080
- Testing
- Glofitamab, Polatuzumab vedotin, Rituximab
- Where
- 229 sites in United States, Argentina and 19 more
- Volunteers
- 1,130 people
- Sponsor
- Hoffmann-La Roche
Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia
Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia
This is a phase I, dose-escalation, open-label clinical trial determining the safety and tolerability of adding Pitavastatin to Venetoclax in subjects with chronic lymphocytic leukemia (CLL) or acute myeloid leukemia (AML).
- Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, AML, Adult, CLL
- Trial name
- NCT04512105
- Testing
- Pitavastatin, Venetoclax
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, Irvine
Leukemia
Laboratory Study of Lymphoblasts in Young Patients With High-Risk Acute Lymphoblastic Leukemia
RATIONALE: Collecting and storing samples of bone marrow and blood from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00896766
- Testing
- loss of heterozygosity analysis, microarray analysis, polymorphism analysis
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Children's Oncology Group
Noncontiguous Stage II Small Lymphocytic Lymphoma, Recurrent Small Lymphocytic Lymphoma
Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This phase II trial is studying how well apolizumab works in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
- Conditions
- Noncontiguous Stage II Small Lymphocytic Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma
- Trial name
- NCT00089154
- Testing
- apolizumab, laboratory biomarker analysis, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.